Melike YÜCEEGE, Sadık ARDIÇ, Serap DURU

Chitinases and lung diseases

nsan vücudunda kitin olmamasına rağmen kitin ve kitinin bazı yapay substratlarını hidroliz eden kitinaz enzimleri eksp- rese edilmektedir. Kitinazların insandaki patofizyolojik fonksiyonları tam olarak bilinmemektedir. Son kanıtlar kitinazların immün yanıt ve inflamatuvar sistemde rol aldığını göstermektedir. Bu derlemede, kitinazların akciğer hastalıklarındaki ro- lünü literatür bilgileri eşliğinde tartıştık.

Chitinases and lung diseases

Chitinase enzymes that hydrolize chitin and some articficial substrates are expressed in human despite lacking of the en- dogenous chitin within the body. Chitinases phatophysiological functions within human are not fully known. Recent evi- dence revealed that chitinases may have role into some processes of immune responses and inflammatory system. In this review, we discuss the role of chitinases in lung diseases based on the available information from the literature.

PDF

___

1. Renkema GH, Boot RG, Muijsers AO, Danker-Koopman WE, Aerts JM. Purification and characterization of human chititi- osidase, a novel member of the chitinase family of proteins. J Biol Chem 1995; 270: 2198-20-2.
2.Kurt I. Chitotriosidase: a new macrophage/phagocyte activa- tion marker. J LSD 2011; 3: 8-15.
3.Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked ele- vation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994; 93: 188-92.
5.Guan SP, Mok YK, Koo KN, Chu KL, Wong WS. Chitinases: bi- omarkers for human diseases. Protein Pept Lett 2009; 16: 490-8.
6.Fusetti F, von Moeller H, Houston D, Rozeboom HJ, Dijkstra BW, Boot RG, et al. Structure of human chitotriosidase. Impli- cations for specific inhibitor design and function of mammali- an chitinase-like lectins. J Biol Chem 2002; 277: 25537-44.
7.Chou YT, Yao S, Czerwinski R, Fleming M, Krykbaev R, Xuan D, et al. Kinetic characterization of recombinant human acidic mammalian chitinase. Biochemistry 2006; 45: 4444-54.
8.Aranson NN Jr, Kuranda MJ. Lysosomal degradation of asn- linked glycoproteins. FASEB J 1989; 3: 2615-22.
9.Kzhshkowska J, Gratcev A, Goerdt S. Human chitinases and chitinas-like proteins as indicators for inflammation and can- cer. Biomarker Insights 2007; 2: 128-46.
10.Sekine T, Masuko-Hongo K, Matsui T. Recognition of YKL-39, a human cartilage related protein, as a target antigen in pati ents with reumatiod arthiritis 2001; 60: 49-54.
11.Buhi WC. Characterization and biological roles of oviduct-spe- sific, oetsrogen-dependent glycoprotein. Reproduction 2002;123: 355-62.
12.Global Strategy for Asthma Management and Prevention 2011 (update). www.ginasthma.org.
13.Zhu Z, Zheng T, Homer RJ, Kim YK, Chen NY, Cohn L, et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 2004; 304: 1678-82.
14.Elias JA, Homer RJ, Hamid Q, Lee CG. Chitinases and chitina- se-like proteins in T(H)2 inflammation and asthma. J Allergy Clin Immunol 2005; 116: 497-500.
15.Vicencio AG, Narain S, Du Z, Zeng WY, Ritch J, Casadevall A, et al. Pulmonary cryptococcosis induces chitinase in the rat. Respir Res 2008; 9: 40.
16.Van Dyken SJ, Garcia D, Porter P, Huang X, Quinlan PJ, Blanc PD, et al. Fungal chitin from asthma-associated home environ- ments induces eosinophilic lung infiltration. J Immunol 2011; 187: 2261-7.
17.Hong JH, Hong JY, Park B, Lee SI, Seo JT, Kim KE, et al. Chi- tinase activates protease-activated receptor-2 in human air- way epithelial cells. Am J Respir Cell Mol Biol 2008; 39: 530- 5.
18.Bierbaum S, Nickel R, Koch A, Lau S, Deichmann KA, Wahn U, et al. Polymorphisms and haplotypes of acid mammalian chitinase are associated with bronchial asthma. Am J Respir Crit Care Med 2005; 172: 1505-9.
19.Ramanathan M, Lee WK, Lane AP.dic mammalian chitinase in chronic rhinosinusitis with nasal polyps. Am J Rhinol 2006; 20: 330-5.
20.Johansen JS. Studies on serum YKL-40 as a biomarker in di- seases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006; 53: 172-209.
21.Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008; 358: 1682-91.
22.Bara I, Ozier A, Girodet PO, Carvalho G, Cattiaux J, Begueret H, et al. Role of YKL-40 in bronchial smooth muscle remode- ling in asthma. Am J Respir Crit Care Med 2012; 185: 15-22.
23. Agapov E, Battaile JT, Tidwell R, Hachem R, Patterson GA, Pi- erce RA, et al. Macrophage chitinase 1 stratifies chronic obst- ructive lung disease. Am J Respir Cell Mol Biol 2009; 41: 379- 84.
24.Letuve S, Kozhich A, Humbles A, Brewah Y, Dombret MC, Grandsaigne M, et al. Lung chitinolytic activity and chitotri- osidase are elevated in chronic obstructive pulmonary disease and contribute to lung inflammation. Am J Pathol 2010; 176: 638-49.
25.Otsuka K, Matsumoto H, Niimi A, Muro S, Ito I, Takeda T, et al. Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease. Respiration 2012; 83: 507-19.
26.Sakazaki Y, Hoshino T, Takei S, Sawada M, Oda H, Takenaka S, et al. Overexpression of chitinase 3-like 1/YKL-40 in lung- specific IL-18-transgenic mice, smokers and COPD. PLoS One 2011; 6: e24177.
27. Grosso S, Margollicci MA, Bargagli E, Buccoliero QR, Perrone A, Galimberti D, et al. Serum levels of chitotriosidase as a mar- ker of disease activity and clinical stage in sarcoidosis. Scand J Clin Lab Invest 2004; 64: 57-62
28. Bargagli E, Margollicci M, Nikiforakis N, Luddi A, Perrone A, Grosso S, et al. Chitotriosidase activity in the serum of patients with sarcoidosis and pulmonary tuberculosis. Respiration 2007; 74: 548-52.
29. Bargagli E, Bianchi N, Margollicci M, Olivieri C, Luddi A, Co- viello G, et al. Chitotriosidase and soluble IL-2 receptor: com- parison of two markers of sarcoidosis severity. Scand J Clin Lab Invest 2008; 68: 479-83.
30. Kzhyshkowska J, Mamidi S, Gratchev A, Kremmer E, Schmuttermaier C, Krusell L, et al. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood 2006; 107: 3221-8.
31.Johansen JS, Milman N, Hansen M, Garbarsch C, Price PA, Graudal N. Increased serum YKL-40 in patients with pulmo- nary sarcoidosis--a potential marker of disease activity? Respir Med 2005; 99: 396-402.
32.Bouzas L, San Jose E, Tutor JC. Chitotriosidase activity in ple- ural effusions. Clin Lab 2007; 53: 449-52.
33. Kim HR, Jun CD, Lee KS, Cho JH, Jeong ET, Yang SH, et al. Levels of YKL-40 in pleural effusions and blood from patients with pulmonary or pleural disease. Cytokine 2012; 58: 336- 43.
34.Hector A, Kormann MS, Mack I, Latzin P, Casaulta C, Kienin- ger E, et al. The chitinase-like protein YKL-40 modulates cys- tic fibrosis lung disease. PLoS One 2011; 6: e24399.
35.Johansen JS. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006; 15: 194-202.
36. Johansen JS, Drivsholm L, Price PA, Christensen IJ. High se- rum YKL-40 level in patients with small cell lung cancer is re- lated to early death. Lung Cancer 2004; 46: 333-40.
37.unker N, Johansen JS, Andersen CB, Kristjansen PEG. Exp- ression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer 2005; 48: 223-31.